NewLimit, the longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, has secured $435 million in Series C funding to advance its first age-reprogramming medicine toward human trials. According to reports from crypto.news, CoinPedia, South San Francisco Business Journal, and Fierce Biotech, the funding round was led by Founders Fund, with participation from new investors Thrive Capital, Greenoaks, and Quiet Capital. Existing backers including Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital also participated in the round. The $435 million round lifted NewLimit's valuation to $3.1 billion, more than triple its level from last year, ranking among the largest private biotech rounds completed this year and underscoring continued investor enthusiasm for longevity-focused drug development.
The company announced on June 2 that it will use the funds to push its first aging reprogramming drug into human clinical trials next year. As reported by crypto.news, CoinPedia, South San Francisco Business Journal, and Fierce Biotech, NewLimit stated that "following breakthrough results, we're bringing longevity medicine to human trials." The company's lead program specifically targets the liver, with NewLimit noting that its liver therapy helped old human liver cells show signs of younger function in early research. The lead program is based on lipid nanoparticle-delivered RNA medicines designed to transiently express combinations of transcription factors in aged liver cells, with the initial focus on alcohol-related liver disease, where aging hepatocytes lose regenerative capacity and become increasingly susceptible to injury. According to Fierce Biotech, co-founder and CEO Jacob Kimmel, Ph.D., initially planned for it to take three or four years to find the right combination, but the winning transcription factor mix became obvious in months rather than years. The company has reported identifying multiple reprogramming payloads that restore youthful function in preclinical liver models, with one of those selected for further development.
NewLimit's lead liver therapy has proven its effectiveness in preclinical models, with the ability to boost regenerative capacity in old livers and make older mice more tolerant of alcohol, as reported by Fierce Biotech. "Older animals actually become severely sedated for many hours," CEO Kimmel explained. "You could see with your naked eye where animals that had received the treatment were resilient, just like young ones were." The company plans to launch phase 1 trials next year focusing on patients with fatty livers from various sources, with phase 2 development then narrowing in on alcohol-related liver disease. Beyond the liver, NewLimit is finalizing transcription factor combinations for two other cell types: endothelial cells within blood vessels and T cells. As reported by Fierce Biotech, Kimmel has his sights set on the vasculature of the kidneys as a potentially transformative treatment for chronic kidney disease (CKD), noting that "CKD treatment is something like half to 1% of U.S. GDP every year." For T cells, he thinks reversing aging can improve immune cell function in diseases like rheumatoid arthritis. The fundraise will also allow NewLimit's team of around 50 staffers to scan a broad swath of other cell types to see which are most amenable to the company's reprogramming technique.
NewLimit focuses on epigenetic reprogramming, a method that aims to restore youthful function in old cells without changing the DNA code itself. According to crypto.news, CoinPedia, South San Francisco Business Journal, and Fierce Biotech, the company's medicines are designed to treat diseases linked to aging by changing how cells behave. The company argues that its work represents one of the most advanced efforts in the emerging field of partial cellular reprogramming, which remains largely preclinical despite substantial investor interest. If the company proceeds on its stated timeline, it would represent one of the first direct tests of an epigenetic reprogramming approach in human subjects. As reported by Fierce Biotech, Kimmel thinks the sky is the limit for NewLimit's cellular reprogramming approach, with the potential to produce a panoply of benefits much like those now seen with GLP-1s. The initial plan is for NewLimit's medicines to be delivered through monthly IV infusions, with the hope of cutting back on dosing frequency in the future.
The funding round places NewLimit among the better-funded private longevity startups, as reported by crypto.news, CoinPedia, South San Francisco Business Journal, and Fierce Biotech. The raise comes as Armstrong continues his broader push into AI and automation, with recent coverage showing that Coinbase used AI to cut account restriction resolution times by 90%. Armstrong has also listed AI tools, stablecoins and tokenization among key finance upgrades, making NewLimit one of his most visible projects outside Coinbase. The company still has no approved product on the market and must demonstrate that early cell-level results can translate into safe and useful medicine during human studies. Notably, Eli Lilly Ventures' continued participation is significant, given Lilly's expanding interest in metabolic and age-related biology following the commercial success of its GLP-1 franchise. Kimmel hopes NewLimit can bring the same "rigorous, deeply scientific approach to developing medicines" to anti-aging that is seen in other areas of biotech, noting that "Is there any other set of diseases that every single person will one day get?"
